This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bentzen, S. M. Articles by Wilson, G. D. Search for Related Content PubMed PubMed Citation Articles by Bentzen, S. M. Articles by Wilson, G. D. Related Articles Related Editorial

Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial

From the Gray Cancer Institute, The Cancer Centre, and Department of Pathology, Mount Vernon Hospital; Department of Oncology, University College London, London, United Kingdom; Department of Radiation Oncology, Marmara University School of Medicine, Istanbul, Turkey; and Barbara Ann Karmanos Cancer Institute, Detroit, MI

Address reprint requests to Søren M. Bentzen, PhD, DSc, Department of Human Oncology, University of Wisconsin Medical School, K4/316 Clinical Sciences Center, 600 Highland Ave, Madison, WI 53792; e-mail: bentzen{at}humonc.wisc.edu

PURPOSE: Accelerated repopulation is a main reason for locoregional failure after fractionated radiotherapy for head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor receptor (EGFR) is a key controller of cellular proliferation in HNSCC, which stimulated the current study to look for a direct link between EGFR status and a possible clinical advantage of accelerated radiotherapy.

PATIENTS AND METHODS: Immunohistochemical staining for EGFR was performed in 304 patients with available pretreatment tumor biopsy material among 918 patients randomized to receive continuous hyperfractionated accelerated radiotherapy versus conventionally fractionated radiotherapy. The EGFR index was estimated as the proportion of tumor cells with EGFR membrane staining.

RESULTS: Significant benefit in locoregional tumor control from continuous hyperfractionated accelerated radiotherapy was seen in patients with HNSCC with high EGFR expression (2P = .010) but not in those with low EGFR expression (2P = .85). EGFR status had no significant effect on survival or rate of distant metastases. The EGFR index was significantly associated with histologic grade and microvessel density. There was moderate support for an association between EGFR status and subsite within the head and neck region but no significant association with Ki-67 index, Ki-67 pattern, p53 index, p53 intensity, bcl-2 expression, or cyclin D1 index.

CONCLUSION: This study indicates a key role for the EGFR receptor in determining the proliferative cellular response to fractionated radiotherapy in HNSCC. It also shows that we can select the dose-fractionation regime that has the greatest chance of benefiting the patient. These results also encourage further development of EGFR targeting combined with fractionated radiotherapy in HNSCC.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials
  Adam P. Dicker and Ulrich Rodeck
  JCO 2005 23: 5437-5439 [Full Text]

This article has been cited by other articles:

				C M West, L Joseph, and S Bhana Epidermal growth factor receptor-targeted therapy Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S36 - S44. [Abstract] [Full Text] [PDF]

				B. Kumar, K. G. Cordell, N. D'Silva, M. E. Prince, M. E. Adams, S. G. Fisher, G. T. Wolf, T. E. Carey, and C. R. Bradford Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer Arch Otolaryngol Head Neck Surg, April 1, 2008; 134(4): 363 - 369. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones and P. Hoskin Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm? J. Clin. Oncol., November 20, 2007; 25(33): 5281 - 5286. [Abstract] [Full Text] [PDF]

				O. Riesterer, L. Milas, and K. K. Ang Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy J. Clin. Oncol., September 10, 2007; 25(26): 4075 - 4083. [Abstract] [Full Text] [PDF]

				C. Elser, L. L. Siu, E. Winquist, M. Agulnik, G. R. Pond, S. F. Chin, P. Francis, R. Cheiken, J. Elting, A. McNabola, et al. Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma J. Clin. Oncol., August 20, 2007; 25(24): 3766 - 3773. [Abstract] [Full Text] [PDF]

				L. R. Henry, H.-O. Lee, J. S. Lee, A. Klein-Szanto, P. Watts, E. A. Ross, W.-T. Chen, and J. D. Cheng Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1736 - 1741. [Abstract] [Full Text] [PDF]

				M. Toulany, U. Kasten-Pisula, I. Brammer, S. Wang, J. Chen, K. Dittmann, M. Baumann, E. Dikomey, and H. P. Rodemann Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair. Clin. Cancer Res., July 1, 2006; 12(13): 4119 - 4126. [Abstract] [Full Text] [PDF]

				A. M. Brade and I. F. Tannock Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure? J. Clin. Oncol., March 1, 2006; 24(7): 1020 - 1022. [Full Text] [PDF]

				A. P. Dicker and U. Rodeck Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials J. Clin. Oncol., August 20, 2005; 23(24): 5437 - 5439. [Full Text] [PDF]